Thursday, February 5th, 2015 at 12:16 PM
Findings of a recently concluded research study (Motherisk Program at The Hospital for Sick Children (SickKids) and by McMaster University and McMaster Children’s Hospital ) revealed that treating postoperative pain with morphine subsequent to the tonsillectomy surgery which is commonly and effectively used to treat childhood obstructive sleep apnea (OSA) may cause life-threatening respiratory problems in some children.
This study identified a significant risk for potentially fatal breathing disruption when morphine is administered at home after surgery to treat pain in children who undergo tonsillectomy with or without adenoidectomy. Prescribing Ibuprofen instead, after Pediatric Sleep Apnea Surgery would be a better option.
The detailed findings of this research study as published in the January 26 online edition of Pediatrics also established that ibuprofen is a safe and effective alternative. Read the rest of this entry
Tuesday, January 22nd, 2013 at 12:50 PM
SleepApneaDisorder/[Press Release]/Asheville, NC /Obstructive Sleep Apnea (OSA) is a common sleep disorder suffered by millions of Americans, and shockingly 3 of 4 sufferers go undiagnosed. OSA constitutes the blocking of the airflow to the respiratory system for periods of time causing the sufferer loss of sleep and overall health.
When treating OSA the bulk of physicians will recommend continuous positive airway pressure or CPAP to their patients. This is a very effective method of treatment, but not all users are happy about wearing a CPAP mask throughout the night. In fact around half of users give up on CPAP therapy within a month.
A new alternative is Provent sleep therapy. Provent, manufactured by Ventus Medical, uses a “MicroValve” design which creates back pressure during exhalation to keep the airway from closing.
Provent was put to the test by Journal Sleep when they trialed its use with 250 sleep apnea sufferers. The study concluded that Provent therapy reduced the effects OSA noticeably during a three month time period.
For more information on Provent visit their website at http://www.proventtherapy.com/index.php A 30 day trial can also be purchased at http://www.cheapcpapsupplies.com/Provent-30-Day-Supply.html
Monday, April 9th, 2012 at 3:02 PM
NovaSom, Inc., the leader in home sleep testing for Obstructive Sleep Apnea (OSA) management, announces it has collaborated with Jefferson School of Population Health to convene the first expert advisory board exploring the impact of undiagnosed OSA on healthcare costs and productivity in the workplace. The unique event brought together top industry thought leaders to discuss new avenues for employers to administer OSA screening, diagnosis and treatment for employees in an effort to manage the growing OSA epidemic within their organization. It took place in Washington, DC on March 9, 2012. Read the rest of this entry
Wednesday, June 15th, 2011 at 8:26 PM
New research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM) in Minneapolis, Minn., quantified the efficacy of mandibular advancement splints (MAS) using a self-administered, at-home device to monitor snoring and sleep-disordered breathing. Clinical assessment of MAS efficacy in the treatment of snoring and obstructive sleep apnea (OSA) is based predominantly on subjective reports by the patient and partner, and less commonly, on the apnea hypopnea index (AHI), which is the average number of pauses in breathing that occur per hour of sleep. The current study used the Sonomat, a portable, unobtrusive device that has sensors contained within a mattress overlay. These sensors measure AHI by detecting and recording snoring, breathing and body movements.
Results show that MAS treatment reduced the average AHI from 10.3 events per hour to 3.8 events per hour. The respiratory event movement index (RMI), which records more types of events than AHI, was reduced from 15.9 events per hour to 7.6 events per hour. Read the rest of this entry
Tuesday, April 19th, 2011 at 8:12 PM
SleepApneaDisorder/ [ Press Release ]/ OKLAHOMA CITY,/— Graymark Healthcare Inc. the nation’s second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), has joined forces with the Oklahoma Heart Institute of the Hillcrest Medical Center in Tulsa, Oklahoma to offer comprehensive sleep medicine services to city residents and the surrounding area.
The 691-bed Hillcrest Medical Center is the flagship of the Hillcrest HealthCare System (HHS). HHS is one of the largest health care systems in the city region, with approximately 5,000 employees who serve the communities of eastern Oklahoma. The Oklahoma Heart Institute (OHI), located on the Hillcrest Medical Center campus, is one of the state’s largest hospitals dedicated exclusively to the prevention, diagnosis and treatment of heart disease.
The new Oklahoma Heart Institute Sleep Care facility features six beds accommodating overnight stays in very comfortable surroundings designed for proper diagnosis, which is followed up by Graymark’s comprehensive sleep medicine program. The facility is designed to accommodate 75 to 125 patients per month, and benefits from Hillcrest’s existing highly-trained medical staff for the administration and management of Graymark’s comprehensive care model. Read the rest of this entry
Thursday, February 24th, 2011 at 9:39 PM
Obstructive sleep apnea (OSA) is a risk factor for a number of cardiovascular conditions. Although homocysteine (Hcy) and cysteine (Cys) are regarded as cardiovascular risk factors, few studies have analyzed Hcy and Cys plasma concentrations in patients with Obstructive sleep apnea (OSA). The aim of this study was to evaluate the role of Hcy and Cys in Obstructive sleep apnea (OSA) in comparison with subjects without Obstructive sleep apnea (OSA)and to determine the possible influence of obesity on these variables.
Patients who submitted to polysomnography studies were recruited to engage in an 8-h fasting period for blood sample withdrawal, physical examination, ECG, and echocardiogram. A subgroup of lean patients with Obstructive sleep apnea (OSA)(BMI < 25 kg/m2) were analyzed to rule out the influence of obesity. Fifteen patients were randomly assigned to participate in a continuous positive airway pressure (CPAP) protocol to assess the influence of Obstructive sleep apnea (OSA)treatment on the obtained measurements.
A total of 75 patients and 75 control subjects matched for age and sex were analyzed. The Cys plasma levels were higher in patients with Obstructive sleep apnea (OSA) compared with control subjects (490.16 ± 67.00 ?mol/L vs 439.81 ± 76.12 ?mol/L, respectively, P < .01); however, the Hcy plasma levels did not differ between groups. Cys plasma levels were also higher in theObstructive sleep apnea (OSA) lean subgroup when compared with lean control subjects (484.21 ± 71.99 ?mol/L vs 412.01 ± 70.73 ?mol/L, respectively, P = .009). There was a significant decrease of Cys plasma levels after 6 months of CPAP effective therapy.
Cys is a potential biomarker of Obstructive sleep apnea (OSA) in obese and nonobese patients and is reduced after effective Obstructive sleep apnea (OSA) treatment.
Tuesday, November 16th, 2010 at 9:42 PM
SleepApneaDisorder/ [Press Release]/ (Raleigh, N.C.) Active Healthcare, an award-winning industry leader in obstructive sleep apnea (OSA) treatment, is marking 20 years of service with the launch of three state-of-the-art IntegraSleep diagnostic centers in Raleigh, Clayton and Smithfield. The fully functional sleep labs provide one-stop-shopping for quality diagnosis and care for this dangerous, often life-threatening condition, utilizing CPAP (Continuous Positive Airway Pressure) systems, the gold standard of sleep apnea treatment.
Headquartered in Raleigh, the IntegraSleep centers were designed by Active Healthcare based on a carefully crafted quality patient care model integrating personalized, extensive follow-up care and maintenance which contributes to the company’s 98% customer satisfaction rate. Read the rest of this entry
Tuesday, November 2nd, 2010 at 8:13 PM
Active Healthcare, an award-winning industry leader in sleep apnea treatment, hosted a meeting of the Durham A.W.A.K.E. (Alert, Well and Keeping Energetic) support group Thursday, October 28 to share meaningful education and resources for managing this dangerous condition.
Participants learned how to deal with challenges in CPAP (Continuous Positive Airway Pressure) therapy, an effective method for treating obstructive sleep apnea. Presenters Julie Shannon and Angela Martinez, sleep specialists with Active Healthcare, were on hand to showcase the latest equipment and perform screenings for obstructive sleep apnea (OSA) in addition to testing attendee CPAP equipment on-site. Read the rest of this entry
Friday, September 10th, 2010 at 10:19 PM
SleepApneaDisorder/[Press Release]/- Agoura Hills, CA (PRWEB) September 10, 2010/The 10th season of The Biggest Loser premieres on Tuesday, September 21st on NBC, and Nationwide Medical, Inc. is proud to be working to support the good health of the contestants.
One of the health concerns related to obesity is Obstructive Sleep Apnea (OSA), a potentially life-threatening condition in which a person has episodes of stopped breathing during sleep. The Biggest Loser provides contestants with comprehensive diagnosis and treatment for OSA. For the past three seasons Nationwide Medical, Inc. has served as the equipment and patient support organization for the CPAP (Continuous Positive Airway Pressure) machines provided by Phillips Respironics. Read the rest of this entry
Saturday, June 26th, 2010 at 4:53 AM
According to new research that received the Graduate Student Research Award on June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea (OSA) may help dentists calculate oral appliance treatment success.
The researchers assessed whether anatomical factors such as craniofacial size, upper-airway soft tissue volume, and/or the anatomical balance between them were associated with mandibular advancement splint (MAS) treatment outcome.
The study included 49 OSA patients. Patients were at least 18 years of age and had mild to severe sleep apnea. They were without other sleep disorders or serious comorbid medical or psychiatric disorders. Read the rest of this entry